Amendments to the Claims

1. (Previously presented) A method for treating sexual arousal disorder comprising:

administering to a female subject in need thereof, an effective amount of an estrogen agonist / antagonist, and optionally,

co-administering an effective amount of a cyclic guanosine 3',5'-monophosphate elevator.

2. (Currently amended) ~~A~~ The method ~~as in~~ of claim 1 wherein said estrogen agonist / antagonist is a compound of ~~the following~~ formula (I):



(I)

wherein:

A is selected from CH_2 and NR;

B, D and E are independently selected from CH and N;

Y is

(a) phenyl, optionally substituted with 1-3 substituents independently selected from R^4;

(b) naphthyl, optionally substituted with 1-3 substituents independently selected from R^4;

(c) C_3-C_8 cycloalkyl, optionally substituted with 1-2 substituents independently selected from R^4;

(d) C_3-C_8 cycloalkenyl, optionally substituted with 1-2 substituents independently selected from R^4;

(e) a five membered heterocycle containing up to two heteroatoms selected from the group consisting of -O-, -NR^2- and -$S(O)_n$-, optionally substituted with 1-3 substituents independently selected from R^4;

(f) a six membered heterocycle containing up to two heteroatoms selected from the group consisting of -O-, -NR^2- and -$S(O)_n$- optionally substituted with 1-3 substituents independently selected from R^4; or

(g) a bicyclic ring system consisting of a five or six membered heterocyclic ring fused to a phenyl ring, said heterocyclic ring containing up to two heteroatoms selected from the group consisting of -O-, -NR^2- and -$S(O)_n$-, optionally substituted with 1-3 substituents independently selected from R^4;

Z^1 is

(a) -$(CH_2)_p$ $W(CH_2)_q$-;

(b) -$O(CH_2)_p$ CR^5R^6-;

(c) -$O(CH_2)_pW(CH_2)_q$-;

(d) -$OCHR^2CHR^3$-; or

(e) -$SCHR^2CHR^3$-;

G is

(a) -NR^7R^8;

(b) 

wherein n is 0, 1 or 2; m is 1, 2 or 3; Z^2 is -NH-, -O-, -S-, or -CH_2-; optionally fused on adjacent carbon atoms with one or two phenyl rings and, optionally independently substituted on carbon with one to three substituents and, optionally, independently on nitrogen with a chemically suitable substituent selected from R^4; or

(c) a bicyclic amine containing five to twelve carbon atoms, either bridged or fused and optionally substituted with 1-3 substituents independently selected from R^4; or

Z^1 and G in combination may be  ;

W is

(a) $-CH_2-$;

(b) -CH=CH-;

(c) -O-;

(d) $-NR^2-$;

(e) $-S(O)_n-$;

(f)  ;

(g) $-CR^2(OH)-$;

(h) $-CONR^2-$;

(i) $-NR^2CO-$;

(j)  ; or

(k) -C≡C-;

R is hydrogen or C_1-C_6 alkyl;

R^2 and R^3 are independently

(a) hydrogen; or

(b) C_1-C_4 alkyl;

R^4 is

(a) hydrogen;

(b) halogen;

(c) C_1-C_6 alkyl;

(d) C_1-C_4 alkoxy;

(e) C_1-C_4 acyloxy;

(f) C_1-C_4 alkylthio;

(g) C_1-C_4 alkylsulfinyl;

(h) C_1-C_4 alkylsulfonyl;

(i) hydroxy (C_1-C_4)alkyl;

(j) aryl (C_1-C_4)alkyl;

(k) $-CO_2H$;

(l) -CN;

(m) -CONHOR;

(n) $-SO_2NHR$;

(o) $-NH_2$;

(p) C_1-C_4 alkylamino;

(q) C_1-C_4 dialkylamino;

(r) $-NHSO_2R$;

(s) $-NO_2$;

(t) -aryl; or

(u) -OH;

R^5 and R^6 are independently C_1-C_8 alkyl or together form a C_3-C_{10} carbocyclic ring;

R^7 and R^8 are independently

(a) phenyl;

(b) a C_3-C_{10} carbocyclic ring, saturated or unsaturated;

(c) a C_3-C_{10} heterocyclic ring containing up to two heteroatoms, selected from -O-, -N- and -S-;

(d) H;

(e) C_1-C_6 alkyl; or

(f) form a 3 to 8 membered nitrogen containing ring with R^5 or R^6;

R^7 and R^8 in either linear or ring form may optionally be substituted with up to three substituents independently selected from C_1-C_6 alkyl, halogen, alkoxy, hydroxy and carboxy;

a ring formed by R^7 and R^8 may be optionally fused to a phenyl ring;

e is 0, 1 or 2;

m is 1, 2 or 3;

n is 0, 1 or 2;

p is 0, 1, 2 or 3;

q is 0, 1, 2 or 3;

or an optical or geometric isomer thereof; or a pharmaceutically acceptable salt, N-oxide, ester, quaternary ammonium salt or prodrug thereof.

3. (Currently amended) ~~A~~ The method ~~as in~~ of claim 2 wherein said estrogen agonist / antagonist is a compound of formula (IA):



(IA)

wherein G is 

;

R^4 is H, OH, F, or Cl; and B and E are independently selected from CH and N or an optical or geometric isomer thereof; or a pharmaceutically acceptable salt, N-oxide, ester, quaternary ammonium salt, or a prodrug thereof.

4. (Currently amended) ~~A~~ The method ~~as in~~ of claim 3 wherein said estrogen agonist / antagonist is (-)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol or an optical or geometric isomer thereof; a pharmaceutically acceptable salt, N-oxide, ester, quaternary ammonium salt, or a prodrug thereof.

5. (Currently amended) ~~A~~ The method ~~as in~~ of claim 4 wherein said estrogen agonist / antagonist is in the form of a D-tartrate salt.

Claims 6.-9. (canceled)

10. (Currently amended) A method for treating sexual arousal disorder comprising:
administering to a female subject in need thereof, an effective amount of an estrogen agonist / antagonist, and ~~as in claim 1~~ further comprising co-administrering a cyclic guanosine 3',5'-monophosphate elevator.

11. (Currently amended) ~~A~~ The method ~~as in~~ of claim 10 wherein said cyclic guanosine 3',5'-monophosphate elevator is a PDE_V phosphodiesterase inhibitor.

12. (Currently amended) ~~A~~ The method ~~as in~~ of claim 11 wherein the PDE_V phosphodiesterase inhibitor is 1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxy-phenyl]sufonyl]-4-methylpiperazine citrate salt.

Claims 13.-39. (canceled)

40. (Currently amended) ~~A~~ The method ~~as in~~ of claim 1 wherein said estrogen agonist / antagonist is selected from the group consisting of tamoxifen, 4-hydroxy tamoxifen, raloxifene, toremifene, centchroman, idoxifene, 6-(4-hydroxy-phenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-naphthalen-2-ol, {4-[2-(2-aza-bicyclo[2.2.1]hept-2-yl)-ethoxy]-phenyl}-[6-hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-methanone, EM-652, EM-800, GW 5638, GW 7604, and optical or geometric isomers thereof; and pharmaceutically acceptable salts, N-oxides, esters, quaternary ammonium salts, and prodrugs thereof.

41. (Currently amended) ~~A~~ The method ~~as in~~ of claim 1 wherein said estrogen agonist / antagonist is a compound selected from the formulas V or VI:



(V)



(VI)

wherein:

R_{1B} is selected from H, OH, -O-C(O)-C_1-C_{12} alkyl (straight chain or branched), -O-C_1-C_{12} alkyl (straight chain or branched or cyclic), or halogens or C_1-C_4 halogenated ethers,

R_{2B}, R_{3B}, R_{4B}, R_{5B}, and R_{6B} are independently selected from H, OH, -O-C(O)-C_1-C_{12} (straight chain or branched), -O-C_1-C_{12} (straight chain or branched or cyclic), halogens, or C_1-C_4 halogenated ethers, cyano, C_1-C_6 alkyl (straight chain or branched), or trifluoromethyl, with the proviso that, when R_{1B} is H, R_{2B} is not OH;

X_A is selected from H, C_1-C_6 alkyl, cyano, nitro, triflouromethyl, and halogen;

s is 2 or 3;

Y_A is the moiety:



wherein:

a) R_{7B} and R_{8B} are independently selected from the group of H, C_1-C_6 alkyl, or phenyl optionally substituted by CN, C_1-C_6 alkyl (straight chain or branched), C_1-C_6 alkoxy (straight chain or branched), halogen, -OH, -CF_3, or -OCF_3; or

b) R_{7B} and R_{8B} are concatenated to form a five-membered saturated heterocycle containing one nitrogen heteroatom, the heterocycle being optionally substituted with

1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C_1-C_4 alkyl, trihalomethyl, C_1-C_4 alkoxy, trihalomethoxy, C_1-C_4 acyloxy, C_1-C_4 alkylthio, C_1-C_4 alkylsulfinyl, C_1-C_4 alkylsulfonyl, hydroxy (C_1-C_4)alkyl, $-CO_2H$, -CN, $-CONHR_{1B}$, $-NH_2$, $-NH(C_1$-$_{C4}$ alkyl), $-N(C_1$-C_4 alkyl)$_2$, $-NHSO_2R_{1B}$, $-NHCOR_{1B}$, $-NO_2$, or phenyl optionally substituted with 1-3 (C_1-C_4)alkyl; or

c) R_{7B} and R_{8B} are concatenated to form a six-membered saturated heterocycle containing one nitrogen heteroatom, the heterocycle being optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C_1-C_4 alkyl, trihalomethyl, C_1-C_4 alkoxy, trihalomethoxy, C_1-C_4 acyloxy, C_1-C_4 alkylthio, C_1-C_4 alkylsulfinyl, C_1-C_4 alkylsulfonyl, hydroxy (C_1-C_4)alkyl, $-CO_2H$, -CN, $-CONHR_{1B}$, $-NH_2$, $-NH(C_1$-C_4 alkyl), $-N(C_1$-C_4 alkyl)$_2$, $-NHSO_2R_{1B}$, $-NHCOR_{1B}$, $-NO_2$, or phenyl optionally substituted with 1-3 (C_1-C_4)alkyl; or

d) R_{7B} and R_{8B} are concatenated to form a seven-membered saturated heterocycle containing one nitrogen heteroatom, the heterocycle being optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C_1-C_4 alkyl, trihalomethyl, C_1-C_4 alkoxy, trihalomethoxy, C_1-C_4 acyloxy, C_1-C_4 alkylthio, C_1-C_4 alkylsulfinyl, C_1-C_4 alkylsulfonyl, hydroxy (C_1-C_4)alkyl, $-CO_2H$, -CN, $-CONHR_{1B}$, $-NH_2$, $-NH(C_1$-C_4 alkyl), $-N(C_1$-C_4 alkyl)$_2$, $-NHSO_2R_{1B}$, $-NHCOR_{1B}$, $-NO_2$, or phenyl optionally substituted with 1-3 (C_1-C_4)alkyl; or

e) R_{7B} and R_{8B} are concatenated to form an eight-membered saturated heterocycle containing one nitrogen heteroatom, the heterocycle being optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C_1-C_4 alkyl, trihalomethyl, C_1-C_4 alkoxy, trihalomethoxy, C_1-C_4 acyloxy, C_1-C_4 alkylthio, C_1-C_4 alkylsulfinyl, C_1-C_4 alkylsulfonyl, hydroxy (C_1-C_4)alkyl, $-CO_2H$, -CN, $-CONHR_1$, $-NH_2$, $-NH(C_1$-C_4 alkyl), $-N(C1$-$C4$ alkyl)$_2$, $-NHSO_2R_{1B}$, $-NHCOR_{1B}$, $-NO_2$, or phenyl optionally substituted with 1-3 (C_1-C_4)alkyl; or

f) R_{7B} and R_{8B} are concatenated to form a saturated bicyclic heterocycle containing from 6-12 carbon atoms either bridged or fused and containing one nitrogen heteroatom, the heterocycle being optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C_1-C_4 alkyl, trihalomethyl, C_1-C_4 alkoxy, trihalomethoxy, C_1-C_4 acyloxy, C_1-C_4 alkylthio, C_1-

C_4 alkylsulfinyl, C_1-C_4 alkylsulfonyl, hydroxy (C_1 -C_4)alkyl, -CO_2 H, -CN, - $CONHR_{1B}$, -NH_2, -NH(C_1-C_4 alkyl), -N(C_1-C_4 alkyl)$_2$, -$NHSO_2R_{1B}$, -$NHCOR_{1B}$, -NO_2, or phenyl optionally substituted with 1-3 (C_1-C_4) alkyl; or an optical or geometric isomer thereof; or a pharmaceutically acceptable salt, N-oxide, ester, quaternary ammonium salt or prodrug thereof.

42. (Currently amended) ~~A~~ The method ~~as in~~ of claim 41 wherein said estrogen agonist / antagonist is the compound, TSE-424, of formula Va below:



(Va)

or an optical or geometric isomer thereof; or a pharmaceutically acceptable salt, N-oxide, ester, quaternary ammonium salt or prodrug thereof.

43. (Currently amended) ~~A~~ The method ~~as in~~ of claim 1 wherein said estrogen agonist / antagonist is EM-652 of formula III below or is EM-800 of formula IV below:



(III)



(IV)

or an optical or geometric isomer thereof; or a pharmaceutically acceptable salt, N-oxide, ester, quaternary ammonium salt or prodrug thereof.

44. (New) A method for treating sexual arousal disorder comprising: administering to a female subject in need thereof, an effective amount of (-)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol or an optical or geometric isomer thereof; a pharmaceutically acceptable salt, N-oxide, ester, quaternary ammonium salt, or a prodrug thereof.

45. (New) The method of claim 44 wherein (-)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol, D-tartrate salt is administered.

46. (New) The method of claim 44 further comprising co-administering an effective amount of a cyclic guanosine 3',5'-monophosphate elevator.

47. (New) The method of claim 46 wherein the cyclic guanosine 3',5'-monophosphate elevator is a PDE_V phosphodiesterase inhibitor.

48. (New) The method of claim 47 wherein the PDE_V phosphodiesterase inhibitor is 1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxy-phenyl]sufonyl]-4-methylpiperazine citrate salt.

49. (New) The method of claim 45 further comprising co-administering an effective amount of 1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxy-phenyl]sufonyl]-4-methylpiperazine citrate salt.

50. (New) The method of claim 45 wherein the female subject is postmenopausal.

51. (New) The method of claim 45 wherein the female subject is pre-menopausal.

52. (New) The method of claim 49 wherein the female subject is postmenopausal.

53. (New) The method of claim 49 wherein the female subject is pre-menopausal.